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BACKGROUND: Patient activation is associated with bet-
ter outcomes in chronic conditions.
OBJECTIVE:Weevaluated the psychometric properties of
the 12-item Altarum Consumer Engagement™ Measure
(ACE-12) in patients with prediabetes.
PARTICIPANTS: ACE-12 was administered to patients in
the Prediabetes InformedDecisions andEducationStudy.
MAIN MEASURES: We conducted an exploratory factor
analysis followed by confirmatory factor analytic models.
We evaluated item response categories using item char-
acteristic curves. Construct validity was assessed by ex-
amining correlations of theACE-12 scaleswith education,
depressive symptoms, self-rated health, hemoglobin A1c,
body mass index, and weight loss.
KEY RESULTS: Participants (n = 515) had a median age
of 58; 56% were female; 17% Hispanic; 54% were non-
White. The scree plot and Tucker and Lewis reliability
coefficient (0.95) suggested three factors similar to the
original scales. One item loaded on the navigation rather
than the informed choice scale. Ordinal alpha coefficients
for the original scales were commitment (0.75); informed
choice (0.71); and navigation (0.54). ICCs indicated that
one ormore of the response categories for 5 of the 12 items
were never most likely to be selected.
Patients with lower education were less activated on the
commitment (r = − 0.124, p = 0.004), choice (r = − 0.085,
p = 0.009), and overall score (r = − 0.042, p = 0.011).
Patients with depressive symptoms had lower commitment
(r = − 0.313, p≤ 0.001) and overall scores (r = − 0.172,
p=0.012). Patients with poorer health scored lower on the
Commitment (r=−0.308,p≤0.001), Navigation (r=−0.137,
p≤0.001), and overall score (r=−0.279, p≤0.001).
CONCLUSION: The analyses provide some support for
the psychometric properties of the ACE-12 in predia-
betic patients. Future research evaluating this tool
among patients with other chronic conditions are
needed to determine whether Q1 (I spend a lot of time
learning about health) should remain in the informed
choice or be included in the navigation scale. Addi-
tional items may be needed to yield acceptable reliabil-
ity for the navigation scale.
KEY WORDS: patient activation; prediabetes; psychometric.
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BACKGROUND
The Centers for Disease Control and Prevention estimates that
more than 1 in 3 American adults have prediabetes and are at
risk of progression to type 2 diabetes and it is deleterious long-
term complications.1 The Diabetes Prevention Program (DPP)
randomized controlled trial showed that the intensive lifestyle
change reduced the incidence of progression to type 2 diabetes
by 58% and metformin decreased the risk by 31%.2Moreover,
the follow-up DPP Outcomes Study demonstrated continuing
positive health outcomes at 10- and 15-year follow-ups.3, 4
Despite this strong evidence supporting the importance of
diabetes prevention, widespread translation of the DPP inter-
vention into real-world settings continues to present
challenges.
Behavioral interventions such as the DPP require engaged
and activated patients to achieve optimal outcomes. Patient
activation is patient self-efficacy for chronic care self-
management and is an indicator of readiness for engagement
in care.5 Patients who are younger,6, 7 more educated,6, 8 have
higher income,6, 8 and better self-rated health tend to be more
activated.6–8 Increases in patient activation and engagement
have been associated with better self-care,7 disease-specific
self-management,9–12 and health outcomes.13, 14
The Altarum Consumer Engagement (ACE)Measure™ is a
patient engagement tool that includes questions about confi-
dence in maintaining a role in one’s health, patterns of seeking
information about health and healthcare, and asking about and
participating in treatment decisions.15 The ACE was
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developed to identify factors that encourage adoption of pa-
tient involvement in their own healthcare and to evaluate
programs designed to facilitate patient decision-making. This
measure of patient engagement is unique in that it addresses
dimensions of engagement that patients need to utilize infor-
mation sources and tools. The ACE was administered in an
online survey of 2079 adults in the general population. Based
on principal components and Rasch analyses, the developers
identified a 6-item Commitment scale, 5-item Informed
Choice scale, 5-item Navigation scale, a 5-item Ownership
scale, and a total activation scale.15 Spearman correlations of
these scales with the 13-item Patient Activation Measure®
ranged from 0.29 to 0.65.
The ACE was administered to a sample of adults with type
II diabetes,16 but its psychometric properties in patients with
prediabetes have not been previously published. We used data
from the Prediabetes Informed Decisions and Education
(PRIDE) study to evaluate the psychometric properties of the
current version of the ACE that consists of 12 of the 21
original survey items (ACE-12, see Table 1) at baseline
(https://altarum.org/sites/default/files/uploaded-related-files/
ACE%20ProductSheet_091615f.pdf).
METHODS
Study Design
We analyzed data from the intervention arm of the PRIDE
study, a cluster-randomized trial of a shared decision-making
(SDM) intervention to help patients select an evidence-based
diabetes prevention strategy (i.e., intense lifestyle change,
metformin, or both). Patients in the intervention arm also had
the option to choose no prevention strategy. The study was
approved by the Institutional Review Board at the University
of California, Los Angeles (IRB#15-000310).
Setting and Participants
The PRIDE study was conducted from 2015 to 2018 at UCLA
Health.17 Twenty primary care clinics in the greater Los
Angeles area were randomized to SDM intervention (10 clin-
ics) or usual care (10 clinics). We used electronic medical
record data to identify eligible patients. Inclusion criteria were
age 18–74, overweight (body mass index [BMI] ≥ 24 kg/m2 or
≥ 22 kg/m2 if Asian) and a diagnosis of prediabetes (HbA1c
5.7–6.4% within the prior 3-months). Patients with diabetes
(i.e., any HbA1c > 6.4%, ICD 250.xx billing code, oral anti-
glycemic medications and/or insulin), chronic kidney disease
(i.e., estimated glomerular filtration rate ≤ 45 ml/min/1.73m2),
active eating disorder(s), and women who had polycystic
ovary syndrome or were pregnant or planning to get pregnant
in the next year were excluded.
After eligible patients were identified, the primary care
providers (PCPs) were notified and a formal standardized
invitation letter signed by the PCP was sent to the patient via
mail. A research assistant then invited patients in the interven-
tion arm to an SDM visit with a clinical pharmacist. PCPs
were also invited to refer patients with prediabetes to the study.
Intervention
The SDM intervention was delivered by clinical pharmacists
embedded in each intervention clinic, who work closely with
the clinic PCPs. The pharmacists used an online decision aid
called “Prediabetes: Which Treatment Should I Use to Prevent
Type 2 Diabetes?” to facilitate the SDM sessions. The decision
aid was created by Healthwise, a national provider of health
information and patient decision support tools for over
35 years. The decision aid provides information about predi-
abetes, compares intensive lifestyle changes and metformin as
two evidence-based options for diabetes prevention, and sum-
marizes the relative risk reduction as well as potential side
effects of each option.17
Measures
We administered the ACE-12 items at baseline to participants
prior to the SDM session and again at 4- and 12-month follow-
up interviews. The ACE-12 uses a 5-point response scale:
strongly disagree, somewhat disagree, neither agree nor dis-
agree, somewhat agree, and strongly agree, and higher scores
represent greater patient engagement. Participants also com-
pleted the Patient Health Questionnaire (PHQ-9) at baseline
and 4- and 12-month follow-up intervals. Other patient char-
acteristics measured at baseline were age, race, ethnicity,
income, education, body mass index (BMI), hemoglobin
A1c, and comorbidities. Patient outcomes for the PRIDE study
are reported in a separate manuscript.17, 18
Analysis
We conducted an exploratory factor analysis of the ACE-12 to
explore whether any items loaded on different factors than
Table 1 ACE-12 items
Patient instructions: On a scale from 0 to 4, tell us if you agree with
the statement.
Q1 I spend a lot of time learning about health.
Q2 Even when life is stressful, I know I can continue to do the
things that keep me healthy.
Q3 I feel comfortable talking to my doctor about my health.
Q4 When I work to improve my health, I succeed.
Q5 I have brought my own information about my health to show
my doctor.
Q6 When choosing a new doctor, I look for information online.
Q7 I can stick with plans to exercise and eat a healthy diet.
Q8 I compare doctors using official ratings about how well their
patients are doing.
Q9 I have lots of experience using the health care system.
Q10 When choosing a new doctor, I look for official ratings based on
patient health.
Q11 Different doctors give different advice; it’s up to me to choose
what’s right for me.
Q12 I handle my health well.
Response choices included 0 = strongly disagree; 1 = somewhat dis-
agree; 2 = neither agree nor disagree; 3 = somewhat agree; and 4 =
strongly agree; ACE 12 Altarum Consumer Engagement 12-item survey
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those identified in the original developmental work. We iden-
tified the number of factors using the Tucker-Lewis reliability
coefficient and the scree plot of eigenvalues with squared
multiple correlations as communality estimates. Good model
fit was evaluated by the comparative fit index (CFI) ≥ 0.95 and
root mean square error of approximation (RMSEA) ≤ 0.06.19
We then fit confirmatory factor analytic models for the original
ACE-12 scales and the variants on these scales suggested by
the exploratory factor analysis. To minimize problems with
overfitting in the sample, we also fit the confirmatory factor
analytic models on a national representative mail and web
survey of over 4000 consumers: https://altarum.org/publica-
tions/right-place-right-time. Good model fit was evaluated by
the comparative fit index (CFI) ≥ 0.95 and root mean square
error of approximation (RMSEA) ≤ 0.06.19
Each response category for items in a survey should have
the highest likelihood of being selected at some area of the
distribution and the categories should be ordered monotoni-
cally with respect to the underlying concept being measured.
We evaluated the ACE-12 response options using item char-
acteristic curves (ICCs) based on the graded responsemodel.20
We then evaluated construct validity by estimating associ-
ations of the ACE-12 scales with education level, depression
symptoms, self-reported health, hemoglobin A1c, BMI at
baseline, and weight loss over 12 months. We hypothesized
that those who chose an intervention versus those who chose
not to adopt an evidence-based prevention strategy after SDM,
those who have more education (greater than a high school
education) and better self-reported health (‘very good” or
“excellent”) would have higher activation scores. We also
hypothesized that more activated patients would be more
likely to complete the DPP and lose 5–7% of their baseline
weight. In contrast, based on evidence from prior literature we
hypothesized that patients with more depressive symptoms
(PHQ-9 score ≥ 5),21 those with higher A1c16, and those
who are obese (BMI ≥ 30.0) would be less activated.15, 16, 22
We report product-moment correlations and associated effect
sizes (Cohen’s d, where d = (2*r)/SQRT(1 − r2). Cohen’s con-
ventions for magnitude of correlations were used: > 0.100 to <
0.243 = small; 0.243 to < 0.371 = medium; and ≥ 0.371 =
large.23
Confirmatory factor analysis models were estimated using
Mplus version 7.24 All other analyses were conducted with
SAS 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
Participant Characteristics
Sample characteristics are given in Table 2. The sample (n =
515) had a mean age of 56 (range = 45–67); 56% were female;
17% were Hispanic, 83% were non-Hispanic. The majority of
participants were White (46%), followed by Asian/Pacific Is-
lander (19%), African American (15%), Native American (1%),
and Other (19%). The mean A1c was 5.95 (SD = 0.2) and mean
BMI was 30.31 (SD = 5.16) at baseline.
Factor Analyses
The scree plot (Fig. 1) and Tucker and Lewis reliability
coefficient (0.95) suggested three underlying factors. The
rotated three-factor solution provided confirmation of the
ACE-12 scales. However, we found that item #1 (I spend a
lot of time learning about health) loaded on the navigation
factor rather than on the informed choice factor.
Fit of the confirmatory factor analysis models are summa-
rized in Table 3. Single-factor models for the original scales
and the variants of the informed choice and navigation scales
fit the data well according to the comparative fit index (i.e., ≥
0.95) but RMSEA values for the commitment and informed
choice scales exceeded the threshold (≤ 0.06) for good fit. The
three-factor model for the revised version of the scales fit the
data better than did the original scales. Ordinal alpha25 was
0.75 for the commitment scale and alphas were similar for the
original and the variants, respectively, of informed choice
(0.71 and 0.78), and navigation (0.54 and 0.62).
Item Characteristic Curves
ICCs are shown in Figure 2 and grouped by ACE-12 scales.
Seven of the items had response categories performing as
expected (i.e., each category had the highest likelihood of
being selected at some area of the distribution and was ordered
monotonically with respect to the underlying concept). There
were issues with the other five items. The neither agree nor
disagree option was never most likely to be chosen for Q2
(commitment, Fig. 2a) and Q6 (informed choice, Fig. 2b). The
strongly disagree option was never most likely to be selected
for Q1 (informed choice, Fig. 2b) andQ5 (navigation, Fig. 2c).
Table 2 Sample Characteristics
Baseline characteristics Consenting SDM
patients (n = 515)
Mean age in
years (SD)
56.28 (11.4)
Female 56%
Race White 46%
AA 15%
Asian 19%
Native American 1%
Other 19%
Ethnicity Hispanic 17%
Non-Hispanic 83%
Education High school graduate 10%
Some college or 2-
year degree
23%
4-year college
graduate
25%
More than 4-year col-
lege graduate
41%
Mean BMI (SD) 30.31 (5.16)
HbA1c % (SD) 5.95 (0.2)
BMI body mass index (kg/m2), HbA1c hemoglobin A1c, SDM shared
decision making, AA African American
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The somewhat disagree and strongly agree options were never
most likely to be chosen for Q3 (navigation, Fig. 2c).
Construct Validity
Correlations of the ACE-12 scales are presented in Table 4.
The pattern of correlations was similar for the original scales
and the variants of the informed choice and navigation scales.
Hence, we summarize only the correlations for the original
scales below. Patients with a high school education or lower at
baseline scored as less activated on the commitment scale (r =
− 0.124, d = − 0.250; p = 0.004), choice scale (r = − 0.085, d =
− 0.171, p = 0.009), and total activation score (r = − 0.042, d =
− 0.084, p = 0.011) at baseline. Education level at baseline was
not associated significantly with the learning about health
scale. Whether an individual selected an intervention and
A1c at baseline were not significantly correlated with activa-
tion scores. Depressive symptoms correlated significantly with
the commitment scale (r = − 0.313, d = − 0.659, p < 0.001) and
total activation score (r = − 0.172, d = − 0.349, p = 0.012). Spe-
cifically, those who scored 5 or higher on the PHQ-5 reported
scored less on the commitment scale and the overall ACE-12
score. Depressive symptoms had the largest magnitude of as-
sociation with the commitment scale (r = − 0.313, d = − 0.659,
p ≤ 0.001). Lastly, patients who self-reported their health as less
than “very good” scored lower on the commitment scale
(r = − 0.308, d = − 0.647, p < 0.001), navigation scale
(r= − 0.137, d= − 0.277, p ≤ 0.001), and total activation score
(r= − 0.279, d= − 0.581, p ≤ 0.001). Except for the choice scale,
all the original ACE scaleswere significantly correlatedwith self-
reported health. Those who were obese (BMI ≥ 30.0) scored less
on the commitment scale (r =− 0.177, d = − 0.360, p = 0.001),
and total activation scale (r =− 0.136, d =− 0.275, p = 0.016).
Weight change over 12 months was not associated with greater
activation scores at baseline.
DISCUSSION
The results of this study provide some support for the original
ACE-12 scales derived by the Duke et al.15 This is important
given the need to better measure and understand patient acti-
vation among patients with chronic conditions for which
behavior change and/or chronic medication use are recom-
mended. Because of the challenges in recruiting and retaining
patients into behavior change programs26 and supporting
patients in adherence to metformin for diabetes prevention,
measuring activation at baseline can be useful in identifying
patients who may benefit from extra support.
Variance Explained
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Fig. 1 Scree plot.
Table 3 Confirmatory Factor Analytic Models
Scale Items Sample Chi
square
Degrees of
freedom
Comparative fit
index
Root mean square error of
approximation
Sample
size
Commitment 2, 4, 7, 12 1A 17.267 2 0.976 0.122 515
2A 106.469 2 0.993 0.113 4055
Informed
choice
1, 6, 8, 10 1B 7.608 2 0.996 0.074 515
2B 77.496 2 0.997 0.097 4052
6, 8, 10+ 1C 76.709 1 0.797 0.384 514
2C 117.414 1 0.979 0.170 4051
Navigation 3, 5, 9, 11 1D 1.189 2 1.000 0.000 515
2D 25.680 2 0.995 0.054 4055
1, 3, 5, 9,
11++
1E 7.506 5 0.992 0.031 515
2E 94.068 5 0.989 0.066 4055
Three factors A, B, D 1 349.566 51 0.885 0.107 515
2 4038.075 51 0.914 0.139 4056
Three factors A, C, E 1 151.122 51 0.961 0.062 515
2 2845.918 51 0.940 0.116 4056
Sample 1 is prediabetes (n =) and sample 2 is https://altarum.org/publications/right-place-right-time
+Variant of scale based on exploratory factor analysis. All other models were categorical. For this model, items were treated as continuous because the
categorical model was just identified (0 degrees of freedom)
++Variant of scale based on exploratory factor analysis
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In terms of hypothesized correlations between patient
activation and other variables, ACE-12 scores in our study
were negatively associated with education, depressive
symptoms, and obesity at baseline. Similarly, our analysis
showed that higher ACE scores correlated with better self-
reported health at baseline. Less patient activation was
observed for those with more depressive symptoms. These
findings are generally consistent with a large body of
literature showing that patients with diabetes and depres-
sion often have difficulty engaging in lifestyle modifica-
tion,27 adherence to medications,28, 29 and report worse
quality of life30 and health outcomes.31 Likewise, consis-
tent with existing literature,15, 22 obesity was associated
with less patient activation in our study.
Interestingly, patients with less education reported higher
activation at baseline. This finding is contrary to prior research
showing less activation among those who are less educated.32
One possible explanation is that study participants with less
education may have had less baseline understanding of predi-
abetes and were highly motivated to enroll in the study and
learn about their condition and prevention strategies to avoid
diabetes. Similarly, patients with more education who were
highly activated may have already raised this issue with their
PCP and/or sought information from other sources and may
have been less interested in participating in SDM for diabetes
prevention. Lastly, we found that better self-reported health at
baseline had the largest association with patient activation.
Our study has several limitations. First, the sample was
comprised of overweight/obese patients with prediabetes
from one large medical system, limiting the generalizabil-
ity of the findings. In addition, construct validity analyses
relied primarily on data gathered at baseline. Future stud-
ies may want to analyze construct validity by exploring
longitudinal relationships among the variables. Hence, the
direction of effects cannot be known from the associations
reported.
Given the relationship between patient activation and en-
gagement and improved health outcomes, our study provides
support for the ACE-12, a brief patient activation tool that can
be easily used and is accessible for research, quality improve-
ment, or clinical use without licensing fees. Future studies
evaluating this tool among patients with multiple chronic
conditions will be needed to determine whether Q1 (I spend
a lot of time learning about health) should remain in the
informed choice or be included in the navigation scale. In
addition, the reliability of navigation scale was suboptimal
(0.54) so it may be important to include additional items to
achieve adequate reliability for this construct.
a) Commitment 
0=Strongly disagree; 1=Somewhat disagree; 2=Neither agree nor disagree; 3=Somewhat agree; and 
4=Strongly agree
b) Informed Choice
c) Navigation
Fig. 2 Item characteristic curves for ACE-12 scales. a Commitment: 0 = strongly disagree; 1 = somewhat disagree; 2 = neither agree nor
disagree; 3 = somewhat agree; and 4 = strongly agree. b Informed choice: 0 = strongly disagree, 1 = somewhat disagree, 2 = neither agree nor
disagree, 3 = somewhat agree, and 4 = strongly agree. c Navigation 0 = strongly disagree, 1 = somewhat disagree, 2 = neither agree nor disagree,
3 = somewhat agree, and 4 = strongly agree.
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